Electrical Brain Stimulation for Treatment of Secondary Symptoms in Multiple Sclerosis - Trial NCT06401928
Access comprehensive clinical trial information for NCT06401928 through Pure Global AI's free database. This phase not specified trial is sponsored by The National Brain Mapping Laboratory (NBML) and is currently Completed. The study focuses on Multiple Sclerosis. Target enrollment is 53 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
The National Brain Mapping Laboratory (NBML)
Timeline & Enrollment
N/A
Feb 28, 2023
Jan 31, 2024
Primary Outcome
Multiple Sclerosis Impact Scale (MSIS-29),and Depression Anxiety Stress Scale-21 (DASS-21),Mini sleep questionnaire (MSQ)
Summary
Multiple Sclerosis (MS) is an autoimmune disease associated with physical disability,
 psychological impairment, and cognitive dysfunction. As a result, the disease burden is high,
 and treatment options are limited. In this randomized, double-blind study, the investigators
 planned to use repeated electrical stimulation and assess mental health-related variables
 (e.g., quality of life, sleep, psychological distress) and cognitive dysfunction in patients
 with MS.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06401928
Device Trial